CUA

(redirected from Cost-utility analysis)
Also found in: Medical, Wikipedia.

CUA

CUA

(Common User Access) SAA specifications for user interfaces, which includes OS/2 PM and character-based formats of 3270 terminals. It is intended to provide a consistent look and feel across platforms and between applications.
References in periodicals archive ?
An economic model was constructed to conduct a cost-effectiveness analysis and a cost-utility analysis following the guidelines outlined by CADTH.
A cost-utility analysis can be used to determine the value of a product or medication on the maintenance and improvement of the length and quality of a patient's life or the allocation of health resources.
Researchers conducting a cost-utility analysis of sentinel lymph node (SLN) mapping and lymph node dissection (LND), both selective and routine, for low-risk endometrial carcinoma (clinical stage 1 disease with grade 1-2 endometrioid histology on preoperative endometrial biopsy), found that the SLN mapping had the lowest costs and the highest quality-adjusted survival of the three strategies.
Cost-utility analysis is a broader form of cost-effectiveness analysis involving the valuation of the outcomes obtained.
Blackhouse and et al., "Canadian cost-utility analysis of initiation and maintenance treatment with anti-TNF-alpha drugs for refractory Crohn's disease," Journal of Crohn's & Colitis, vol.
In some of these studies it was accompanied by a cost-utility analysis (3 studies), one study exclusively exploited the cost-utility analysis and one cost-minimization analysis.
Articles that had carried out full economic evaluation, including cost-effectiveness analysis, cost-utility analysis, and cost-benefit analysis were included.
Accordingly, this study was aimed to determine economic viability of the PGx of warfarin in the VACHS-affiliated anticoagulation clinic in San Juan, PR through a cost-utility analysis in warfarin-treated Puerto Rican patients, utilizing an Incremental Cost Utility Ratio (ICUR) and establishing a willingness to pay of $50,000 per QALY gained, as well as to explore the range of potential outcomes using sensitivity analysis.
Lewis, "UK cost-utility analysis of rituximab in patients with rheumatoid arthritis that failed to respond adequately to a biologic disease-modifying antirheumatic drug," Current Medical Research and Opinion, vol.
A cost-utility analysis of hysterectomy, endometrial resection and ablation and medical therapy for menorrhagia.
A recent effectiveness guidance document by the Center for Medical Technology Policy (CMTP) on incorporating patient-reported outcomes in oncology research recommends the inclusion of PRO in prospective clinical CER studies in oncology, assessment of HRQL, and use of a measure that enables cost-utility analysis [1].